|
|
 |
 | ||
|
|
| ||
 |
Program Direction |
|
Dr. Stuart H. Orkin - Head of the Combined Program in Hematology/Oncology at Children's Hospital Boston and Dana-Farber Cancer Institute, David G. Nathan Professor of Pediatrics at Harvard Medical School, Investigator of the Howard Hughes Medical Institute, and Chair of the Dept. of Pediatric Oncology at Dana-Farber. Dr. Orkin is a world-renowned researcher who has made extraordinary contributions to our understanding of the molecular basis of thalassemias, and to the mechanisms that regulate the lineage specification and differentiation of hematopoietic stem cells in their transitions to blood cells, the biology of stem cells, and the molecular mechanisms responsible for cancer. Dr. Orkin discovered the technique of position cloning when he cloned the gene responsible for chronic granulomatous disease. He also initiated the molecular dissection of von Willebrand's disease through his cloning of vWF, and the understanding of molecular hematopoiesis through the cloning of GATA1, FOG1 and other transcription factors that control the differentiation of hematopoietic stem cells. These and other seminal contributions have been recognized by his election to the National Academy of Sciences and the American Academy of Arts and Sciences, by selection to be the President of the American Society of Clinical Investigation, and by receipt of numerous prizes, including the Dameshek and E. Donnall Thomas Awards from the American Society of Hematology and the E. Mead Johnson Award from the American Academy of Pediatrics.
|
|
|
Dr. David A. Williams - Chief, Division of Hematology/Oncology and Director of Clinical and Translational Research at Children's Hospital Boston, and Leland Fikes Professor of Pediatrics at Harvard Medical School. Dr. Williams replaces Dr. Samuel E. Lux, who served as as division chief for 23 years. He joins us from Cincinnati Children's Hospital where he was the Director of the Division of Experimental Hematology and Associate Director for Translational Research. Prior to that he directed pediatric research at the Indiana University School of Medicine. Dr. Williams is an internationally renowned researcher, with major interests in the study of blood stem cell biology, blood formation, leukemia, and the treatment of genetic blood disorders using gene therapy. He has won numerous prestigious awards for his research, including the Dameshek Award for research in hematology and the E. Mead Johnson Award for research in pediatrics. He was an Investigator of the Howard Hughes Medical Institute for 16 years and is a member of the National Academy of Sciences Institute of Medicine. Dr. Williams trained in hematology/oncology at Children's and Dana-Farber Cancer Institute. During his fellowship research at the Whitehead Institute, he developed techniques for introducing genes into human hematopoietic cells using retroviruses that are still used in gene therapy today. Dr. Williams has a strong interest in translational research. He codiscovered Interleukin-11 (NeumegaTM) and is currently collaborating with Amgen on a small molecule inhibitor of Rac GTPases for potential use in treating cancer. He is also leading gene therapy trials in patients with Fanconi anemia. In addition to his scientific prowess, Dr. Williams is a superb clinician and directed the Clinical Hematology Service at Children's during his years as a faculty member.
|
|
|
Dr. Lisa R. Diller - Clinical Director of Pediatric Oncology at Dana-Farber Cancer Institute and Children's Hospital Boston, and Associate Professor of Pediatrics at Harvard Medical School. Dr. Diller's research focuses on the treatment of patients with solid tumors, particularly neuroblastoma, and the study of survivors of childhood cancer. She is a national expert in both of these areas. She is the founder and director of the Perini Family Survivor Center and the Medical Director of the David B. Perini, Jr. Quality of Life Program, which is devoted to clinical care for and research on childhood cancer survivors. She is also a member of the national Children's Oncology Group neuroblastoma steering committee. Dr. Diller is an outstanding teacher and mentor and a wonderful clinician and leader.
|
|
|
Dr. Holcombe E. Grier - Fellowship Program Co-Director and Head of the Fellowship Program Training Committee, Associate Professor of Pediatrics at Harvard Medical School, and Associate Chief of Clinical Pediatric Oncology at Dana-Farber Cancer Institute. Dr. Grier is a superb teacher and mentor, an outstanding clinician and an excellent clinical investigator. His excellence in teaching was recognized by receipt of the Charles A. Janeway Award, which is given to only one physician each year by the medical housestaff at Children's Hospital Boston and is generally regarded as the highest honor bestowed by the institution. As a clinician and clinical scientist, Dr. Grier has developed a national reputation in the treatment of the sarcomas of childhood, particularly Ewing sarcoma.
|
|
|
|
|
|
